Business · 08/06/2012Updated: 10/17/2026 · 1 min read
Pfizer Withdraws FDA Approval for CELEBREX Indication for Familial Adenomatous Polyposis
Summary
Pfizer, Inc. has voluntarily withdrawn its FDA approval for the familial adenomatous polyposis (FAP) indication of CELEBREX (celecoxib) Capsules, allowing the company to waive a hearing process.